(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The trial involved 9,650 … Read the full press release
(IN BRIEF) Two European studies presented at the ESC Congress 2024 reveal the significant impact of urban noise pollution on cardiovascular health. The DECIBEL-MI study from Germany found that young heart attack patients had been exposed to higher levels of … Read the full press release
Posted in Business, Financial, France, Germany, Government, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged Cardiovascular risk, DECIBEL-MI study, ENVI-MI study, ESC, France, Germany, heart health, noise pollution
(IN BRIEF) Novo Nordisk, a global healthcare company, has reported the headline findings from the SELECT cardiovascular outcomes trial. This double-blinded study assessed the impact of subcutaneous once-weekly semaglutide 2.4 mg in comparison to placebo as an adjunct to standard … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Cardiovascular risk, Martin Holst Lange, Novo Nordisk, Obese Adults, overweight, SELECT Trial, Semaglutide 2.4 mg, Wegovy, wellness
(PRESS RELEASE) LUXEMBOURG, 29-Nov-2021 — /EuropaWire/ — Luxembourg Institute of Health (LIH), a public biomedical research organisation, has announced that a project called YOUNG 50 and funded by the European Commission launches in Luxembourg with the aim to screen and … Read the full press release
Posted in European Union, Healthcare, Lithuania, Luxembourg, News, Romania, Society
Tagged cardiovascular disease, Cardiovascular risk, Centre for Disease Control and Prevention, CVD, European Commission, Lithuania, Luxembourg, Obese, overweight, risk screening program, Romania, screening program, smokers, YOUNG 50
SOPHIA ANTIPOLIS, 07-Aug-2017 — /EuropaWire/ — Pneumonia or sepsis in adults that results in hospital admission is associated with a six-fold increased risk of cardiovascular disease in the first year, according to research published today in the European Journal of Preventive … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
